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Background: Attention deficit-hyperactivity disorder (ADHD) is the most prevalent
neuropsychiatric condition in childhood. ADHD is a multifactorial trait with a strong
genetic component. One neurodevelopmental hypothesis is that ADHD is associated
with a lag in brain maturation. Sphingolipids are essential for brain development
and neuronal functioning, but their role in ADHD pathogenesis is unexplored. We
hypothesized that serum sphingolipid levels distinguish ADHD patients from unaffected
subjects.
Methods: We characterized serum sphingolipid profiles of ADHD patients and two
control groups: non-affected relatives and non-affected subjects without a family history
of ADHD. Sphingolipids were measured by LC-MS/MS in 77 participants (28 ADHD
patients, 28 related controls, and 21 unrelated controls). ADHD diagnosis was based on
the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR). Diagnostic criteria
were assessed by two independent observers. Groups were compared by parametrical
statistics.
Results: Serum sphingomyelins C16:0, C18:0, C18:1, C24:1, ceramide C24:0, and
deoxy-ceramide C24:1 were significantly decreased in ADHD patients at 20–30% relative
reductions. In our sample, decreased serum sphingomyelin levels distinguished ADHD
patients with 79% sensitivity and 78% specificity.
Conclusions: Our results showed lower levels of all major serum sphingomyelins in
ADHD. These findings may reflect brain maturation and affect neuro-functional pathways
characteristic for ADHD.
Keywords: ADHD, sphingolipids, sphingomyelins, ceramides, biomarker, endophenotype
Introduction
Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral condition characterized by
persistent, cross-situational and developmentally inappropriate levels of inattention, hyperactivity,
and impulsiveness (American Psychiatric, 2000). ADHD affects 8–12% of children of school
age and is thus the most common pediatric neuropsychiatric disorder (Polanczyk et al., 2014).
Abbreviations: GLM, general linear model; ROC, receiver operating characteristic; SM, sphingomyelin.
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ADHD is considered a multifactorial trait in which genetic
factors account for about 75–80% of the phenotypic variance
and environmental factors, such as premature delivery, perinatal
hypoxia, maternal smoking, alcohol consumption, and others,
may contribute to the remaining 20–25% (Thapar et al., 2013;
Li et al., 2014; Polanczyk et al., 2014). The therapeutic effect
of stimulants has led to wide acceptance of the dopaminergic
hypothesis, a dysfunction in catecholaminergic/dopaminergic
transmission, as a core mechanism for the disorder (Swanson
et al., 2000; Tripp and Wickens, 2009), although associations
identified between ADHD and monoaminergic gene variants
account for a very modest risk effect (Li et al., 2014). A recent
genome-wide association study suggested that exploration of
alternative/complementary etiological factors related to neuritic
outgrowth and maturation should be considered (Bralten
et al., 2013). This is in line with neuroimaging studies, which
increasingly suggest white/gray matter anomalies in prefrontal
cortex, temporo-parietal regions, striatum, and cerebellum in
ADHD patients (Casey et al., 2007; Silk et al., 2009; Helpern et al.,
2011; Nagel et al., 2011; Peterson et al., 2011; de Zeeuw et al.,
2012; Cortese et al., 2013; Greven et al., 2015). In this context, a
prominent neurodevelopmental hypothesis proposes that ADHD
involves a lag in brain maturation (Castellanos et al., 2002; Rubia,
2007; Shaw et al., 2007).
Sphingolipids, highly abundant in nervous tissue, affect
neuronal and glial proliferation, differentiation, apoptosis as
well as membrane permeability to Ca2+ and K+, relevant
to the generation and propagation of the nervous impulse
and neurotransmitter release (Colombaioni and Garcia-Gil,
2004; Gielen et al., 2006; Posse De Chaves and Sipione,
2010). Cell and animal models underscore the key function
of sphingolipids in neurite growth and mass of cerebellum
and forebrain (Hirabayashi and Furuya, 2008; Imgrund et al.,
2009; Ginkel et al., 2012). Deficiency of ceramide synthase-2
that generates sphingolipids with C22–C24 fatty acyl chains,
results in 50% loss of compacted myelin and 80% loss of CNS
myelin basic protein (Imgrund et al., 2009). Similarly, a 60%
reduction of myelin-associated glycoprotein in cerebellum and
forebrain characterizes mice deficient in ceramide synthase-
1, the enzyme that generates C18:0 sphingolipids. Hyperactive
behavior characterizes mice deficient of ceramide synthase -6 that
generates C16:0 sphingolipids (Ebel et al., 2013). In premature
infants, supplementation of milk with sphingomyelins has
been associated with significant improvements in attention and
memory measurements at 18 months, suggesting positive effects
on neurobehavioral development (Tanaka et al., 2013). Based on
these observations and reported correlations between serum and
CSF sphingolipids (Mielke et al., 2010, 2011) we hypothesized
that serum sphingolipid levels distinguish ADHD patients from
unaffected subjects. The exploration of sphingolipids as potential
pathogenic factors and/or biomarkers for ADHD is new.
Methods
Participants
This case-control study was designed to compare serum
sphingolipid profiles of ADHD patients with two independent
control groups: unaffected first degree relatives of ADHD
patients, sharing housing, and dietary patterns with the index
cases and unaffected subjects with no family history of ADHD.
We studied 77 subjects belonging to one of the following 3
groups: (1) ADHD patients (n = 28; 14 males), (2) unaffected
first-degree relatives of ADHD patients [mother, father, or
siblings of the index cases included in group (1), n = 28;
4 males], and (3) unaffected participants without a family
history of ADHD (also referred to as unaffected unrelated
subjects or non-related controls, n = 21; 8 males). Table 1
summarizes relevant characteristics of the three groups. ADHD
diagnosis was based on the criteria of the Diagnostic and
Statistical Manual of Mental Disorders in all cases (DSM IV-
TR) (American Psychiatric, 2000). Criteria were assessed by at
least two independent observers (most commonly: parents and
teachers), according to current guidelines (Seixas et al., 2012;
Hauk, 2013). All participants were recruited from an ongoing
study exploring the role of polyunsaturated fatty acids in ADHD
pathogenesis (Henríquez-Henríquez et al., 2012). Participants
with clinical evidence/anamnestic antecedent of major systemic
and neurological illness and taking ω-3/ω-6 supplementation
were excluded from the study.
ADHD patients were between 5 and 18 years old (median =
12.7 years; 25th percentile = 11 years; 75th percentile =
17 years) and referred from general psychiatric/neurological
and family medicine outpatient clinics serving a medium
income area of urban Santiago, Chile. Seventeen patients
were clinically classified as ADHD combined subtype, 10
patients as predominantly inattentive, and one patient as
predominantly hyperactive-impulsive (American Psychiatric,
2000). This distribution agrees with the subtype prevalence
generally described for clinically referred ADHD patients across
the globe (Willcutt, 2012). All patients were treated with
either d-amphetamine or methylphenidate in doses ranging
10–30mg/day. A medication free washout period of 24 h was
required prior to blood analyses (t1/2 for methylphenidate at
10–20mg/kg: 2–4 h; t1/2 for d-amphetamine 6–12 h).
ADHD diagnosis was excluded from the unaffected groups
(groups 2 and 3) by means of a brief clinical interview exploring
DSM-IV-TR criteria (American Psychiatric, 2000). We required
that unaffected relatives participating in this study were living
and eating in the same home with the ADHD index case,
to control dietary and other unknown environmental factors.
Group 3 (consisting of unaffected participants without a family
history of ADHD) were children recruited from a medium-
income school in the same urban area and healthy adults
recruited from the same family medicine services at the time
of general annual checkup. Family history of ADHD was
anamnestically explored in group 3 considering first and second
degree relatives. Ages of unaffected relatives (group 2) ranged
from 10 to 64 years (median = 34 years; 25th percentile =
23.6 years; 75th percentile = 43 years). In group 3 (non-related
controls) ages ranged from 7 to 51 years (median = 23.5 years;
25th percentile = 12.3 years; 75th percentile = 35.6 years).
Because age and gender distributions significantly differ among
the 3 groups (p = 0.01 and p = 0.001, respectively), we
controlled for those in all subsequent statistical analyses.
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TABLE 1 | Relevant clinical and epidemiological characteristics in the three groups studied.
Non-related controls Related controls ADHD patients
Number of subjects 21 28 28
Age (years) 25th percentile 12.3 23.6 11
Median 23.5 34 12.8
75th percentile 34.8 43 17
Gender Male 8 4 14
Female 13 24 14
Number of DSM IV-TR positive criteria Inattention 1 (0–3) 1 (0–5) 7 (4–9)
Hyperactivity/Impulsivity 1 (0–3) 1 (0–5) 6 (0–9)
ADHD subtype Predominantly hyperactive-impulsive N/A N/A 1
Predominantly inattentive N/A N/A 10
Combined type N/A N/A 17
Treatment D-Amphetamine N/A N/A 7
Methylphenidate N/A N/A 21
Age is described in terms of the percentiles 25th, 50th, and 75th due to non-Gaussian distribution of this variable inside the groups.
All procedures performed as part of this study have been
approved by the Ethics Committee of Pontificia Universidad
Católica de Chile. The study was fully explained to children and
their parents, and they both agreed to participate by signing
written consent and assent forms.
Serum Sphingolipid Analysis
Blood samples were obtained after an 8 h fast. Samples were
centrifuged and obtained serum was stored at −20◦C until
analysis.
Sphingolipid profiles include the following molecular species:
(1) sphinganine-1-phosphate and sphingosine-1-phosphate; (2)
ceramides C16:0, C18:0, C20:0, C22:0, C24:0, and C24:1;
dihydroceramides C18, C18:1, C24:0, and C24:1; deoxy-
ceramide C16:0 and C24:1 and deoxy-dihydroceramides C16:0
and C24:1; (3) sphingomyelins (SM) SM C16:0, SM C18:0,
SM C18:1, and SM C24:1. Their relative location in the
sphingolipid metabolic pathway is summarized in Figure 1.
Sphingolipid levels were quantified by high performance liquid
chromatography-triple quadrupole-tandem mass spectrometry
(HPLC-MS/MS) on an Agilent 1200 HPLC system, equipped
with an Agilent C18 column as reported (Bui et al., 2012).
Briefly, sphingolipids were extracted overnight in a 1:30 v/v
solution of diethylamide 10%/dichloromethanol: methanol 1:1,
at room temperature using sphingomyelin C12 (0.120µM) as
internal standard. HPLC conditions were: Mobile phase A
was methanol/water/chloroform/formic acid (55:40:5:0.4 v/v);
Mobile phase B was methanol/acetonitrile/chloroform/formic
acid (48:48:4:0.4 v/v). The chromatography column was first
pre-equilibrated for 6 s. After this period, the gradient gradually
increased to 60%mobile phase B and 100%mobile phase B. 100%
mobile phase B was held for 1.9min. Flow rate was 0.6ml/min.
Injection into the HPLC-MS/MS system was set at 3µl. All
measurements were performed in triplicates.
Data Analysis
The final serum level for each patient and analyte was
calculated by averaging triplicate measurements. Subsequent
statistical analyses were performed on these final levels. Average
inter-assay imprecision for sphingolipid quantification was
8.7% (ranging from 2.5% for sphingomyelins to 12.3% for
deoxyceramides).
Statistical Analysis
The normal distribution of individual sphingolipids was
evaluated by the Kolmogorov-Smirnov test after outlier
detection/rejection by the Tukey method (Tukey, 1977). All
sphingolipids were normally distributed. Group differences were
examined by general linear models (GLM) using sphingolipid
levels as the dependent variable and “clinical group,” “age,”
and “gender” as covariates. “Clinical group” was defined as a
categorical variable with 3 levels: ADHD patients, unaffected
relatives of ADHD patients and unaffected unrelated subjects.
Post-hoc pair-wise comparisons were performed when significant
effect for the variable “clinical group” was detected and
significance was maintained as p = 0.05. This approach was
verified using the adaptive procedure described by Benjamini
and Hochberg (BH-A) for controlling the False Discovery Rate
(FDR) (Kromrey and Hogarty, 2002), with the same results in
terms of the rejection of the null hypothesis. All analyses were
conducted using SAS 9.2 software (SAS Institute, Cary, North
Carolina).
To evaluate the ability of the assayed sphingolipids for
correctly classifying ADHD affected and non-affected subjects,
we performed Receiver Operating Characteristic (ROC) analyses
(Fawcett, 2004), using the method of Delong et al for the
calculation of the standard error of the area under the curve
(DeLong et al., 1988).
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FIGURE 1 | Sphingolipid metabolic pathways. Ceramide is central in
sphingolipid metabolism, produced by de novo and recycling pathways.
Serine and palmitoyl-CoA are substrates of serine palmitoyl-transferase
(SPT), the rate limiting enzyme of de novo synthesis that generates
ketosphinganine from serine and palmitoyl-CoA (bottom). Ketosphinganine is
reduced to form sphinganine that is N-acylated by ceramide synthases with
fatty acids of different chain lengths to form dihydroceramides.
Dihydroceramides are desaturated by dihydroceramide desaturase (DES) to
generate ceramides. Ceramides can be metabolized to sphingomyelin or
glycosphingolipids. SPT generates deoxyceramides when utilizing alanine
instead of serine. Notably, deoxyceramides only originate from de novo
synthesis. The recycling pathway generates ceramides from sphingomyelin
and other complex sphingolipids. Ceramidases degrade ceramides and
release sphingoid bases, which are reutilized for complex sphingolipid
biosynthesis or phosphorylated to sphingosine-1-phosphate. Boxed
compounds indicate molecular species assayed in this study.
Results
Analysis of Sphingomyelins
ADHD patients had lower serum levels of all assayed SM
species. The “clinical group” effect was significant in all species
after controlling by age and gender (SM C16:0 p < 0.0001;
SM C18:1 p = 0.05; SM C18:0 p = 0.01; SM 24:1 p =
0.001) (Figure 2). Pairwise comparisons confirmed significant
differences between ADHD patients and both control groups for
all the species, except for sphingomyelin C18:1, where ADHD
patients were significantly different only when compared to
related controls. The biggest relative difference was observed for
sphingomyelin C24:1, which was 21% lower in ADHD patients.
Relative differences in other species ranged from 13% (SMC16:0)
to 18% (SM C18:0).
Analysis of Ceramides, Dihydroceramides, and
Deoxy-ceramides
Analysis of ceramides (C16:0, C18:0, C22:0, C24:1, and C24:0)
showed 20% lower ceramide C24:0 in ADHD patients compared
to unaffected relatives (post-hoc pair-wise comparison p = 0.02)
(Figure 3). This difference was maintained when comparing
ADHD patients with non-related controls (post-hoc pair-
wise comparison p = 0.04). We explored dihydroceramide
levels to evaluate if decreased ceramide C24:0 could originate
from decreased de novo synthesis and found no differences
between groups (data not shown). To further evaluate the
FIGURE 2 | Serum levels for sphingomyelins in ADHD patients, their
unaffected relatives and unaffected subjects without family history of
ADHD. Serum sphingomyelin levels were measured by LC-MS/MS as
described. Results are expressed in µM. Plots represent individual values for
all data included in the analysis. Mean and SEM are indicated by bars.
UR-Controls, Unaffected subjects without family history of ADHD; R-Controls,
Unaffected relatives of ADHD patients. *p = 0.0002, **p = 0.05, ***p = 0.014,
****p = 0.0014, † p = 0.0005, ‡ p = 0.0003, § p = 0.01, ||p = 0.0045,
¶ p = 0.046, †† p = 0.013, and ‡‡ p = 0.0004.
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FIGURE 3 | Serum levels for ceramides and deoxy-ceramides in
ADHD patients, their unaffected relatives and unaffected subjects
without family history of ADHD. Serum ceramide levels were measured
by LC-MS/MS as described. Results are expressed in µM. Plots represent
individual values for all data included in the analysis. Mean and SEM are
indicated by bars. UR-Controls, Unaffected subjects without family history of
ADHD; R-Controls, Unaffected relatives of ADHD patients. *p = 0.03,
**p = 0.018, ***p = 0.003, ****p = 0.01, and † p = 0.0411.
de-novo pathway we also measured deoxy-ceramides, which
originate obligatory through the de-novo pathway (Figure 1).
We measured the four most abundant species for which external
standards are available (deoxy-dihydroceramides C16:0, C24:1,
and deoxy-ceramides C16:0, C24:1) and found deoxy-ceramide
C24:1 to be 30% lower in ADHD patients compared to related
controls (pairwise comparison p = 0.003; p-value “clinical
group” effect in GLM = 0.01) (Figure 3). A similar, but not
significant trend was observed when comparing deoxy-ceramide
C24:1 in ADHD patients to levels found in non-related controls
(relative difference = 14%; post-hoc pairwise comparison
p = 0.1).
Sphingosine-1-Phosphate and
Sphinganine-1-Phosphate Levels
We evaluated levels of sphingosine-1-phosphate and
sphinganine-1-phosphate among the three groups, of
potential interest as sphingosine-1-phosphate has been linked to
regulation of neuronal excitability and neurotransmitter release
(Colombaioni and Garcia-Gil, 2004). Mean serum sphingosine-
1-phosphate was 1.55µM (SD = 0.38µM) in ADHD patients.
Concentrations did not differ (p = 0.48) from those found
in unaffected relatives (mean ± SD = 1.44 ± 0.38µM) or
unaffected controls without a family history of ADHD (mean ±
SD = 1.59 ± 0.38µM). Mean serum sphinganine-1-phosphate
was 0.23µM (SD = 0.008µM) in ADHD patients, 0.2µM
(SD = 0.01µM) in unaffected relatives and 0.22µM (SD =
0.007µM) in non-related controls. Sphinganine-1-phosphate
concentrations were not different between groups (p = 0.27).
These findings suggest that serum sphingoid bases are not
different in ADHD patients.
Low Serum Sphingolipids Distinguish ADHD
Patients from Unaffected Subjects
We built Receiver Operating Characteristic (ROC) curves to
evaluate whether any of the assayed sphingolipids would
discriminate between ADHD-affected and unaffected subjects
with adequate levels of sensitivity and specificity. The best
detection accuracy was obtained for total SM levels (the sum of all
detected SM), with an AUC of 0.81 (CI: 0.71 to 0.89; p < 0.0001),
79% sensitivity and 78% specificity (Figure 4). The estimated
negative predictive value, considering 10% ADHD prevalence,
was 97%.
Sphingolipids as Potential Endophenotypes for
ADHD
To explore whether any of our findings can be considered as
a candidate endophenotype (or intermediate phenotype) for
ADHD, we evaluated if they would fit an endophenotype-
characteristic stair-like distribution, with the highest frequency
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FIGURE 4 | Receiver operating characteristic (ROC) curve and
confusion matrix for total sphingomyelins. (A) Receiver operating
characteristic curve (ROC). The point of best discrimination was determined to
be 134 uM total sphingomyelins. Total sphingomyelins refers to all assayed
sphingomyelins. (B) Contingency table (confusion matrix) for total
sphingomyelins. Total sphingomyelins <134µM provide a sensitivity of 79%
and specificity of 78%. Considering a prevalence of 10% for ADHD, the
negative predictive value for total sphingomyelins is 97%.
of the marker among affected subjects, intermediate frequencies
among unaffected subjects with positive family antecedents
and the lowest frequencies among unaffected subjects without
family antecedents of the condition. Based on the ROC curves,
we chose the cut-off that best discriminated between ADHD
and unaffected subjects for each analyte and built contingency
tables that enabled us to evaluate the frequency of subjects
below and above the cut-off inside the three clinical groups. The
expected stair-like distribution was observed for SM C24:1 and
deoxy-ceramide C24:1 (p-values: p < 0.0001, and p = 0.01,
respectively) (Figure 5). As a confirmatory approach and in
order to adjust significances by age and gender effects, we
also adjusted a GLM using the variable “clinical group” as a
quantitative variable with three levels, being the highest for
ADHD patients and the lowest for non-related controls, with
similar results (p-values: p < 0.001 for SM C24:1 and p = 0.03
for deoxy-ceramide C24:1).
Discussion
In this pilot study, we characterized sphingolipid serum profiles
in ADHD patients and two control groups: (1) unaffected first
degree relatives of ADHD patients who live and eat with their
index ADHD case and (2) unaffected subjects without a family
FIGURE 5 | SM C24:1 and deoxy-ceramide C24:1 may be ADHD
endophenotypes. Contingency graphs showing the number of subjects
below and above cutoff among ADHD patients, their unaffected relatives and
non/related unaffected controls for (A) SM C24:1 and (B) deoxy-ceramide
C24:1. UR-controls, Unaffected subjects without family history of ADHD;
R-Controls, Unaffected relatives of ADHD patients.
history of ADHD among their first and second degree relatives.
Sphingolipids and their metabolites are important for neuronal
functioning (Buccoliero and Futerman, 2003; Colombaioni and
Garcia-Gil, 2004), but serum concentrations have not been
reported in the context of ADHD.
The major finding of our study is that serum levels for all
major sphingomyelins and select ceramides are lower in ADHD
patients compared to related -as well as to- unrelated controls.
The biggest relative difference in sphingomyelin levels among the
groups was observed for the long chain sphingomyelin C24:1,
with a 21% reduction in the ADHD group when compared
to the control groups. It is noteworthy that although more
than 100 different subspecies of sphingomyelins have been
described in human serum, the four species included in this study
account for as much as 60% of total SM, while each one of the
remaining non-assayed species account for about 0.5% of total
SM (Quehenberger et al., 2010).
Figure 1 shows a schematic representation of sphingolipid
metabolic pathways with emphasis on those metabolites that are
relevant to our results. Ceramide can originate from de novo
synthesis from serine and palmitoyl-CoA, or from the recycling
pathway through catabolism of complex sphingolipids. Serine-
palmitoyl transferase can alternatively utilize alanine instead of
serine resulting in the synthesis of deoxyceramides. Degradation
of ceramide yields sphingoid bases that can be phosphorylated
to sphingosine-1-phosphate. Based on this scheme, potential
causes for observed decreased serum sphingomyelins are (1)
decreased sphingomyelin uptake or synthesis or (2) increased
sphingomyelinase activity. Neither of these mechanisms was
specifically evaluated in the current study.
Ceramide C24:0 was decreased 20% and deoxy-ceramide
C24:1 -which originates exclusively from the de-novo pathway-
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was decreased 30% in ADHD patients. Notably, the low
levels of ceramide C24:0 and deoxy-ceramide C24:1 in
ADHD patients are not paralleled by a decrease in any
dihydroceramide, suggesting that ceramide synthase-2
activity (which generates dihydroceramides with acyl chains
C22–24) might not be impaired in ADHD. Comparable
concentrations of all dihydroceramide species also suggest
that low ceramide C24:0 and deoxy-ceramide C24:1 are
not compensated by increased synthesis of other species
through the de-novo pathway (see Figure 1). Thus, potential
causes for observed decreased ceramides are (1) selectively
decreased activity of dihydroceramide desaturase (DES) that
converts dihydroceramides to ceramides, or (2) increased
conversion of ceramide C24:0 into sphingosine, ceramide-1-
phosphate or glucosylceramides, which were not evaluated.
Decreased ceramide C24:0 might also be caused by decreased
sphingomyelin C24:0, not measured in this study. Such a
mechanism, however, cannot explain decreased deoxy-ceramide
C24:1, since this ceramide is not a degradation product of
sphingomyelin or any other more complex sphingolipids and
must be generated de-novo. Notably, decreased nervonic acid
(C24:1) has been reported in red blood cells of ADHD patients
(Chen et al., 2004).
Whether serum sphingolipid profiles reflect brain
sphingolipid metabolism is not known. For patients with
HIV and Alzheimer’s disease, a significant correlation between
ceramide and sphingomyelin levels in plasma and CSF have been
reported (Mielke et al., 2010, 2011), but no studies have explored
these correlations in the general population. Future research is
necessary to evaluate if plasma sphingolipid levels can be related
to changes in CSF and brain tissue in ADHD.
The interpretation and extrapolation of our results must
consider some limitations. First, cases and controls are not age-
gender matched and we observe significant differences in the
distributions for these variables among the groups (see Table 1).
As a consequence, we are not able to completely rule-out a
confounding effect for age and gender, even though we controlled
by these variables in all subsequent statistical analyses. To date,
there is very limited data about physiological changes associated
to age and gender in serum sphingolipids. A recent study
describes a specific gender effect for the serum levels of several
sphingomyelins, with higher values for women (Ishikawa et al.,
2014), but we did not observe significant gender effects in anyone
of the studied ceramide/sphingomyelin species in our sample
(Table 2). The same study did not show age specific effects for any
of the sphingolipids that we report to be significantly associated
with ADHD. We explored eventual correlations between age
and serum sphingolipid levels in our sample and did not find
significant correlations for anyone of the analytes included in
this study, except for ceramide C24:1, which did not present
significant differences between ADHD patients and controls
(Table 3). We also performed a subsample analysis considering
all participants from 5 to 18 years old (mean age ADHD group=
12.3 years 95% CI = 11.25 − 13.42; mean age controls = 12.2
years 95% CI= 10.87− 13.7 p = 0.72) and were able to confirm
our observations in terms of significantly lower levels for all
sphingomyelins (SM C16:0 p = 0.0028; SM C18:0 p = 0.0088;
TABLE 2 | Gender effects for the studied ceramides and sphingomyelins.
Analyte F-value p-value
SM C16:0 0.09 0.77
SM C18:0 0.04 0.85
SM C18:1 1.89 0.18
SM C24:1 0.12 0.73
C16:0 0.01 0.93
C18:0 1.39 0.24
C20:0 2.14 0.13
C22:0 0.35 0.55
C24:0 0.73 0.39
C24:1 0,19 0.67
Deoxy-ceramide C24:1 0.12 0.73
Reported effects are controlled by age and clinical group.
SM C18:1 p = 0.018; SM C24:1 p = 0.0038). Of note, we also
performed ROC analysis for total SM levels using an age-matched
subsample, finding sensitivity and specificity values comparable
with those reported for the complete sample (AUCsubsample =
0.82 CI: 0.66 – 0.93, p < 0.0001; 82% sensitivity and 78%
specificity), suggesting that results are not affected by age.We also
observed the same i.e., decreased albeit non-significant trends
for ceramide C24:0 and deoxy-ceramide C24:1 in the sub-sample
analyses (C24:1 F = 1.1 p = 0.3 and deoxy-ceramide C24:1 F =
2.36 p = 0.14, respectively). As a second limitation, none of
our patients were treatment naïve and we cannot rule-out that
our findings correspond to a chronic treatment effect instead
of being an actual pathogenic marker/factor. Acute treatment
effects, on the other hand, were prevented by requiring a 24 h
washout period for medication. Finally, our restricted sample
size did not allow us to perform analyses by clinical subtype and
we are not able to distinguish whether the reported results are
applicable to all clinical subgroups or were driven by a specific
clinical subtype. We also might be underpowered for detecting
some differences of eventual clinical importance. As an example,
taking into account the overall variation of our data, we estimate
that our study is not able to detect differences less than 20% for
themajority of the ceramides. In light of the potential relevance of
the results reported by this pilot study, future research addressing
these limitations and including the exploration of additional
confounders, such as co-morbidities, is mandatory.
Strengths of our study include (1) the presence of a
comparison group of first degree relatives that live and eat with
the index case to control for a potential “diet” effect and for
other unknown environmental factors and (2) the inclusion of
an additional control group of unaffected subjects without a
family history of ADHD to assess replication of findings. This is
relevant because differences observed between ADHD patients
and their relatives could reveal either a true characteristic of
ADHD patients, or reflect compensatory mechanisms exerted
by unaffected relatives to constitutional risk factors shared with
ADHD patients.
In addition, the experimental design of this study allows
to explore whether sphingolipid levels fulfill the distribution
criteria proposed by Gottesman and Gould for endophenotypes
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TABLE 3 | Age-serum level correlations for the studied ceramides and
sphingomyelins.
Analyte Pearson correlation coefficient p-value
SM C16:0 0.14 0.91
SM C18:0 −0.02 0.88
SM C18:1 0.07 0.57
SM C24:1 0.15 0.2
C16:0 0.17 0.14
C18:0 0.07 0.54
C20:0 0.14 0.25
C22:0 0.22 0.07
C24:0 0.11 0.38
C24:1 0.25 0.03
Deoxy-ceramide C24:1 0.016 0.89
Reported correlations correspond to partial correlations using gender and
presence/absence of ADHD as co-variants.
of psychiatric disorders (Gottesman and Gould, 2003).
Endophenotypes are quantifiable markers of genetic liability
for non-mendelian complex diseases, which constitute a more
“direct” expression of the gene effect than the disorder itself,
since they are influenced by fewer genetic and environmental
variables. They do not need to be specific, since they might signal
common pathogenic mechanisms between related disorders. Our
results suggest that sphingomyelin C24:1 and deoxy-ceramide
C24:1 qualifies for the expected endophenotype distribution
and should be further explored as potential endophenotypes
for ADHD. Notably, regions containing genes encoding key
enzymes in the sphingolipid metabolism i.e., serine-palmitoyl
transferase (SPTLC1, SPTLC3, SPTSSB) and sphingomyelinases
(SMPD1, SMPD4, SMPD3A), have been mapped in association
with ADHD (Asherson et al., 2008; Romanos et al., 2008;
Rommelse et al., 2008).
In conclusion, our results show decreased serum levels of
sphingomyelins SM C16:0, SM C18:0, SM C18:1, and SM C24:1,
of ceramide C24:0 and deoxy-ceramide C24:1 in ADHD patients
compared to related and unrelated controls. This is the first study
of serum sphingolipids in ADHD patients. Our data suggest
that sphingomyelin SM C24:1 and deoxy-ceramide C24:1 are
potential markers for ADHD (endophenotypes) that could reflect
pathomechanisms relevant to the disorder.
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